AURIGENE ONCOLOGY LIMITED
Location
Karnataka
Founded
2001-08-10
Website
Risk Signals
17 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about AURIGENE ONCOLOGY LIMITED
Live alerts from global media, monitored by Business Radar
2025-06-05 (pharmatutor.org)
Aurigene Oncology Hiring Senior Scientist in Medicinal Chemistry |
Must have hands on experience in linker- payload synthesis and overall understanding of ADC. Should be able to design and execute synthesis of complex drug linkers and ADC payloads.
Read more
2025-04-29 (biotecnika.org)
Aurigene Oncology Biotech Research Jobs, Apply Now
Aurigene Oncology Biotech Research Jobs, Apply Now. Biological Sciences Jobs at Aurigene Oncology. MSc Biotech Jobs.
Read more
2025-04-21 (biotecnika.org)
Scientist – Cell & Gene Therapy Position at Aurigene Oncology in Bangalore | Apply Now!
Scientist – Cell & Gene Therapy Position at Aurigene Oncology in Bangalore | Ph.D. Genetics Jobs in India. M.Sc./M.Tech in Biotechnology Jobs
Read more
2025-04-03 (webwire.com)
Edity Therapeutics Enters into a Strategic Co-Development Partnership with Aurigene Oncology to Advance a Novel Cell Therapy Program for Solid Tumors |
Edity Therapeutics Limited and Aurigene Oncology Limited (AOL), a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited, a clinical-stage biotechnology company, announced a strategic collaboration to create novel cell therapy medicines for difficult-to-treat solid tumors. , , , , The partnership is bolstered by government grants awarded to both companies. Aurigene Oncology secured grant from the India-Israel Industrial R&D and Technology Innovation Fund, while Edity received non-diluti...
Read more
2025-03-21 (biotecnika.org)
Research Associate – CAR-T Manufacturing Job | Aurigene Oncology Limited – Apply Now
Research Associate - CAR-T Manufacturing Job at Aurigene. Aurigene Oncology is hiring Research Associate in CAR-T Manufacturing in Bengaluru
Read more
2025-01-23 (businesswire.com)
Dr. Reddy's Q3 & 9MFY25 Financial Results
Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024.
Read more
2025-01-23 (businesswire.com)
Dr. Reddy’s Q3 & 9MFY25 Financial Results | Business Wire
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024.
Read more
2024-11-12 (bioworld.com)
Aurigene Oncology discovers new SMARCA2 and SMARCA4 degradation inducers |
Aurigene Oncology Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety via a linker acting as SMARCA2 and/or SMARCA4 degradation inducers reported to be useful for the treatment of cancer.
Read more
2024-11-07 (bioworld.com)
Aurigene Oncology presents new dual inhibitors of PD-L1 and adenosine receptors |
Aurigene Oncology Ltd. has divulged compounds acting as dual antagonists of adenosine receptor A2A (ADORA2A) and programmed cell death 1 ligand 1 (CD274; PD-L1) reported to be useful for the treatment of cancer.
Read more
2024-09-16 (expresshealthcare.in)
ICMR signs agreements for first-in-human clinical trials of four new molecules –
ICMR partners with industry leaders for trials on molecules targeting multiple myeloma, Zika, influenza, and chronic lymphocytic leukaemia
Read more
2023-07-11 (bioworld.com)
Aurigene and Olema present new KAT6A inhibitors for cancer |
Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have divulged fused benzoisoxazolyl compounds acting as histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
Read more
2022-12-16 (moneycontrol.com)
Dr Reddy's subsidiary Aurigene Oncology stops clinical trial for psoriasis drug in US
After phase 2 results, the company's CEO said the drug will not add desirable benefit to patients with moderate to severe, psoriasis, hence, the firm decided to stop the clinical development of AUR101 as an oral drug in psoriasis.
Read more